This may be the first clinical evidence of LGSO benefit from ALK inhibitors, to provide evidence for the use of ALK inhibitors in more ovarian cancer patients with EML4‐ALK fusion and promoting new ideas for the study of EML4‐ALK targets in ovarian cancer. The gene discussed is EML4; the disease is ovarian carcinoma.